However, research published in the journal Nature Communications suggests that a hormone called hepcidin could be the cause of the skin condition. Hepcidin is a hormone that helps you to regulate ...

Rusfertide, described in the news release as a first-in-class investigational hepcidin mimetic peptide therapeutic, has already received Orphan Drug designation and Fast Track designation from the ...

The Japanese pharma licensed rusfertide, an investigational injectable hepcidin mimetic designed to treat a rare chronic blood disorder called polycythemia vera (PV), back in January 2024.

Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received Orphan Drug designation and Fast Track designation from the U.S. Food & Drug Administration ...

Learn more about whether Alvotech or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades ...

The Japanese pharma group is paying $300 million upfront for rights to rusfertide, an injectable hepcidin mimetic currently in the pivotal phase 3 VERIFY trial in PV that could generate ...

Hereditary hemochromatosis is an inherited iron overload disorder caused by inappropriately low hepcidin secretion leading to increased duodenal absorption of dietary iron, most commonly in C282Y ...